CYLD and carcinoma: Interestingly, the basal cell adenomas and carcinomas harbor mutations of CYLD in exons 9–11, while only basal cell adenocarcinomas harbor CYLD mutations involving exons 12–20, corresponding to the ubiquitin-specific hydrolase domain.